Merck and Moderna said on October 22, 2026 that investigational intismeran autogene plus Keytruda reduced the relative risk of melanoma recurrence or death by 42% versus Keytruda alone. Phase 3 INTerpath-001 involved patients with surgically resected stage IIB–IV disease.
Clinical evidence is not approval
Overall-survival data remain immature and regulatory engagement continues. The result is neither marketing approval nor a revenue guarantee.
What investors should watch
Regulatory review and commercial manufacturing feasibility are the next tests. Follow our healthcare-company coverage.
Discover more from Market News | أخبار الأسواق
Subscribe to get the latest posts sent to your email.